September 17, 2020 10:57 AM EDT
News Briefing

News brief­ing: Check­point reads out new in­ter­im mC­SCC da­ta; Taysha eyes $125M for its flash IPO

Jason Mast

Editor

Nicole DeFeudis

Editor

Check­point Ther­a­peu­tics has read out up­dat­ed in­ter­im Phase I da­ta for its an­ti-PD-L1 an­ti­body cosi­be­limab in a reg­is­tra­tion-en­abling co­hort of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

Bio­Marin turns to ex-Roche deal­mak­er James Sabry to build ‘next ver­sion’ of 27-year-old com­pa­ny

An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Te­va’s MS drug and gener­ics to add black box warn­ing for ana­phy­lax­is

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times